The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Almost 300 million people globally have chronic hepatitis B
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
Evinova will operate as a separate health-tech business within AstraZeneca
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface”
Subscribe To Our Newsletter & Stay Updated
